Long, Bitter Legal Saga Over CRISPR Patents Likely Over As Appeals Court Rules Against University Of California
It's unlikely the dispute over CRISPR research between the Broad Institute of MIT and Harvard and the University of California will go to the Supreme Court.
Appeals Court Upholds CRISPR Patents Awarded The Broad Institute
A federal appeals court on Monday struck another blow against the University of California’s hopes of invalidating key CRISPR patents held by the Broad Institute of MIT and Harvard, ruling unanimously that a U.S. patent board correctly concluded that the Broad’s patents did not “interfere” with those that UC had applied for. Barring an appeal to the U.S. Supreme Court, which is highly unlikely to accept the case, or a request for the full U.S. Court of Appeals for the Federal Circuit to consider the case, the long and bitter legal saga is largely over, at least in the U.S. (The fight over CRISPR patents in Europe continues.) (Begley, 9/10)
San Francisco Chronicle:
Court: UC Berkeley Cannot Patent Gene Editing Research
A study published in 2012 by a team of scientists led by UC Berkeley biologist Jennifer Doudna was the first to show how the so-called CRISPR technology could be used to alter DNA. Six months later, a researcher with the Broad Institute, affiliated with Harvard and MIT, issued a study describing the use of the same genetic technology in human cells. UC argued that the publication had lifted the basic idea of its own earlier work and challenged Broad’s patent applications. (Egelko, 9/10)